Fennec Pharmaceuticals (TSE:FRX) Director Rostislav Christov Raykov Acquires 4,609 Shares of Stock

Posted by James Quigley on Oct 11th, 2025

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Rostislav Christov Raykov acquired 4,609 shares of the business’s stock in a transaction dated Wednesday, October 8th. The shares were bought at an average price of C$3.38 per share, for a total transaction of C$15,578.42. Following the acquisition, the director owned 2,697,927 shares of the company’s stock, valued at approximately C$9,118,993.26. This represents a 0.17% increase in their ownership of the stock.

Fennec Pharmaceuticals Stock Performance

FRX opened at C$12.30 on Friday. Fennec Pharmaceuticals Inc. has a 52-week low of C$5.65 and a 52-week high of C$13.83. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. The company has a market cap of C$342.33 million, a P/E ratio of -27.33 and a beta of 2.48. The firm’s 50-day moving average price is C$12.20 and its 200-day moving average price is C$10.73.

About Fennec Pharmaceuticals

(Get Free Report)

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.